Ex vivo expanded human ILC2s (Ex ILC2s) can kill tumor cells through the secretion of GzmB, mediated by the DNAM-1–CD112/CD155 receptor-ligand interaction (Figure 2C) (199). The gene discussed is GZMB; the disease is neoplasm.